Your Feed

Filter by
See content from
Back to the latest
Avatar
Rauchka60DAF
Myelodysplastic Syndromes Discussion • July 4
Blood transfusion reactions.
I have MDS and CMML……i amhetting CBC weekly. About every three weeks a get two units of red blood cells. I have several antigens and antibodies so it is difficult to to get a matching donor. I have been getting incompatable blood with the doctor signing off and have had no issues until the last two transfusioms. I am Ok getting the blood at the hospital but the next morning I get violent shaking and a temp of about 102. We have changed my cross and match to Mondays to see if a donor can be found that matches. So I can get blood a little later in the week. What happens if no match can be found??? PS. NO CHEMO has helped all failed.
Avatar
Annborell
Multiple Myeloma Discussion • July 3
Cevostamab trials
Has anyone started a trial with Cevostamab? If so how is it going and what health center are you receiving treatment?
Avatar
slhenk9
Multiple Myeloma Discussion • July 3
trial drug
has anyone yet started the trispecific drug...JNJ vs taclisamab....and is there anything you can do to protect your taste buds
Thumbnail for A New CELMoD Contender: SUCCESSOR-2 Highlights Mezigdomide’s Potential in Myeloma | EHA 2026
Playlist: EHA 2026

A New CELMoD Contender: SUCCESSOR-2 Highlights Mezigdomide’s Potential in Myeloma | EHA 2026

Video details & playlist
Thumbnail for Real-World Treatment Sequencing After CAR-T vs Bispecific Antibodies in Multiple Myeloma | EHA 2026
Playlist: EHA 2026

Real-World Treatment Sequencing After CAR-T vs Bispecific Antibodies in Multiple Myeloma | EHA 2026

Video details & playlist
Thumbnail for Can We Prevent Taste Loss with Talquetamab? TALISMAN Study Brings New Hope | EHA 2026
Playlist: EHA 2026

Can We Prevent Taste Loss with Talquetamab? TALISMAN Study Brings New Hope | EHA 2026

Video details & playlist
Avatar
tritchie01
Multiple Myeloma Discussion • July 2
Faster trial
Information
Thumbnail for Optimizing Bispecific Therapy in Myeloma: Choosing the Right Time for Treatment | EHA 2026
Playlist: EHA 2026

Optimizing Bispecific Therapy in Myeloma: Choosing the Right Time for Treatment | EHA 2026

Video details & playlist
Thumbnail for MajesTEC-9 Results : Teclistamab Outperforms PVd & Kd in Relapsed Myeloma: | EHA 2026
Playlist: EHA 2026

MajesTEC-9 Results : Teclistamab Outperforms PVd & Kd in Relapsed Myeloma: | EHA 2026

Video details & playlist
Thumbnail for A New Frontier in Myeloma: mRNA-2808 Targets BCMA, GPRC5D & FcRH5 with One Therapy | ASCO 2026
Playlist: EHA 2026

A New Frontier in Myeloma: mRNA-2808 Targets BCMA, GPRC5D & FcRH5 with One Therapy | ASCO 2026

Video details & playlist